The genetic alteration of PT did not appear to affect its immunogenicity, since the median PT antibody levels were of the same magnitude as those that we have observed after a fifth dose of a combined tetanus, low dose diphtheria and acellular pertussis vaccine (TRIAXIS®, Sanofi Pasteur). This evidence concerns the gene F2 and pertussis.